SSRIs significantly increase the risk of both serious and non-serious adverse events .
The potential small beneficial effects seem to be outweighed by harmful effects .
Background The evidence on selective serotonin reuptake inhibitors ( SSRIs ) for major depressive disorder is unclear .
Methods Our objective was to conduct a systematic review assessing the effects of SSRIs versus placebo , ‘ active ’ placebo , or no intervention in adult participants with major depressive disorder .
Effect of fluoxetine on noradrenergic mediated growth hormone release: A double blind, placebo-controlled study
Twelve patients with DSM-III-R major depressive illness were tested for growth hormone ( GH ) response to desipramine ( DMI ) , a noradrenergic ( NA ) reuptake inhibitor . The response is mediated by NA alpha 2 receptors . They were then r and omly assigned to treatment under double-blind conditions with either fluoxetine , the highly selective serotonin reuptake inhibitor or placebo . After 4 weeks they were retested . Fluoxetine but not placebo was effective in promoting recovery in four of the six patients treated . Patients treated with fluoxetine showed a significant decrease in DMI-mediated GH release irrespective of therapeutic outcome . This is consistent with marked alteration of NA function and raises questions as to the selectivity of fluoxetine
SSRIs significantly increase the risk of both serious and non-serious adverse events .
The potential small beneficial effects seem to be outweighed by harmful effects .
Background The evidence on selective serotonin reuptake inhibitors ( SSRIs ) for major depressive disorder is unclear .
Methods Our objective was to conduct a systematic review assessing the effects of SSRIs versus placebo , ‘ active ’ placebo , or no intervention in adult participants with major depressive disorder .